文献速递中医内科中药与中成药合理使用

雷公藤治疗结缔组织病相关间质性肺病的系统评价与Meta分析

Efficacy and Safety of Tripterygium Wilfordii Hook. F for Connective Tissue Disease-Associated Interstitial Lung Disease:A Systematic Review and Meta-Analysis.
PubMed 文献 · Front Pharmacol · 2021-06-10

该系统评价与Meta分析检索10个数据库至2021年5月,纳入9项RCT共650例结缔组织病相关间质性肺病患者,比较雷公藤联合常规治疗与单用常规治疗。结果显示联合治疗可改善肺功能、HRCT积分、炎症指标及临床症状,但DLCO%无显著差异,不良反应发生率无统计学差异,结论需更大样本严格设计的RCT证实。

要点

  • 雷公藤联合常规治疗可显著改善CTD-ILD患者FVC%、FEV1%和TLC%。
  • 联合治疗可降低HRCT积分、ESR、CRP和类风湿因子水平。
  • DLCO%及呼吸困难改善无统计学差异,不良反应发生率无显著差异。

核心结论

  • 雷公藤联合常规治疗在改善CTD-ILD患者症状、肺功能和实验室指标方面优于单用常规治疗。
  • 因纳入研究样本量较小,上述发现需进一步严格设计的RCT证实。

研究设计与样本

  • 系统评价与Meta分析,检索PubMed、Embase、Cochrane Library、Web of Science、PsycINFO、Scopus、CNKI、万方、维普和CBM数据库至2021年5月。
  • 纳入比较雷公藤联合常规治疗与单用常规治疗的随机对照试验,最终纳入9项RCT共650例患者。
  • 遵循PRISMA清单,采用Cochrane手册5.1.0和RevMan 5.3进行数据分析与质量评价。

主要发现

  • 联合治疗组治疗后FVC%较对照组显著提高(MD=8.68,95%CI 5.10–12.26,p<0.00001)。
  • 联合治疗组FEV1%显著提高(MD=11.24,95%CI 6.87–15.61,p<0.00001),TLC%亦显著提高(MD=5.28,95%CI 0.69–9.87,p=0.02)。
  • DLCO%组间无显著差异(MD=4.40,95%CI -2.29–11.09,p=0.20)。
  • 联合治疗组HRCT积分降低(MD=-0.65,95%CI -1.01至-0.30,p=0.0003),ESR降低(MD=-9.52,95%CI -11.55至-7.49,p<0.00001)。
  • 联合治疗组CRP降低(MD=-8.42,95%CI -12.47至-4.38,p<0.0001),类风湿因子降低(MD=-25.48,95%CI -29.36至-21.60,p<0.00001)。

临床怎么用

  • 对CTD-ILD患者,可考虑在常规治疗基础上联合雷公藤以改善肺功能、HRCT表现及炎症指标。
  • 联合治疗对咳嗽、Velcro啰音和气短等症状可能有益,但需关注个体化评估。
  • DLCO%和呼吸困难改善不显著,临床决策时应结合患者具体情况综合判断。

局限性

  • 纳入研究样本量相对较小,结论需进一步严格设计的RCT证实。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: Tripterygium wilfordii Hook. F (TwHF), a Chinese herbal medicine used to treat CTD-ILD patients in China, has been previously found to have immunoinhibitory, antifibrotic and anti inflammatory effects. It has also shown good results in treating autoimmune and inflammatory diseases. Objectives: This systematic review and meta-analysis aims to evaluate the efficacy and safety of TwHF for CTD-ILD. Methods: A systematic search was performed on PubMed, Embase, Cochrane Library, Web of Science, PsycINFO, Scopus, CNKI, Wanfang, VIP, and CBM databases up to May 2021. Randomized controlled trials (RCTs) comparing TwHF plus conventional therapy versus conventional therapy alone were included. We followed the PRISMA checklist, and applied Cochrane handbook 5.1.0 and RevMan 5.3 for data analysis and quality evaluation of the included studies. Results: Based on Cochrane handbook 5.1.0, nine RCTs consisting 650 patients met the inclusion/exclusion criteria and were selected for further analysis. The obtained data showed significant improvement in lung function with TwHF plus conventional treatment compared with conventional treatment (post-treatment FVC% (MD= 8.68, 95%Cl (5.10, 12.26), p < 0.00001), FEV1% (MD = 11.24, 95%Cl (6.87, 15.61), p < 0.00001), TLC% (MD = 5.28, 95%Cl (0.69, 9.87), p = 0.02)], but no significant difference in the post-treatment DLCO% [(MD = 4.40, 95%Cl (-2.29, 11.09), p = 0.20)]. Moreover, the data showed that TwHF combined with conventional treatment significantly reduced the HRCT integral of patients [MD = -0.65, 95% (-1.01, -0.30), p = 0.0003], the level of erythrocyte sedimentation rate (MD = -9.52, 95%Cl (-11.55, -7.49), p < 0.00001), c-reactive protein (CRP) (MD = -8.42, 95%Cl (-12.47, -4.38), p < 0.0001), and rheumatoid factor (MD = -25.48, 95%Cl (-29.36, -21.60), p < 0.00001). Compared to conventional therapy, TwHF combined with conventional therapy significantly improved clinical effects (RR = 1.33, 95%Cl (1.17, 1.51), p < 0.0001), in five trials with 354 patients. In terms of improvement of symptoms and signs, the TwHF group showed a more significant improvement than the conventional treatment group (Cough (MD = -0.96, 95%Cl (-1.43, -0.50), p < 0.0001), velcro rales (MD = -0.32, 95%Cl (-0.44, -0.20), p < 0.00001), shortness of breath (MD = -1.11, 95%Cl (-1.67, -0.56), p < 0.0001)], but no statistical difference in dyspnea (MD = -0.66, 95%Cl (-1.35, 0.03), p = 0.06). There was no statistical significance in the incidence of adverse reactions. Conclusion: The performed meta-analysis indicated that TwHF combined with conventional treatment was more beneficial to patients for improving symptoms, lung function and laboratory indicators. As it included studies with relatively small sample size, the findings require confirmation by further rigorously well-designed RCTs.

来源:Front Pharmacol,查看原文。版权归原作者所有。

引用

  1. Li Y, Zhu W, He H, et al. Efficacy and Safety of Tripterygium Wilfordii Hook. F for Connective Tissue Disease-Associated Interstitial Lung Disease:A Systematic Review and Meta-Analysis. Front Pharmacol. 2021. PMID: 34177599. doi:10.3389/fphar.2021.691031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。